Asia Pacific Academy of Science Pte. Ltd. (APACSCI) specializes in international journal publishing. APACSCI adopts the open access publishing model and provides an important communication bridge for academic groups whose interest fields include engineering, technology, medicine, computer, mathematics, agriculture and forestry, and environment.
Rinalt®: a new adjunctive therapeutic option for rhinitis
Vol 36, Issue 2S2, 2022
Abstract
Rhinitis is an inflammatory disease of the nose. The rhinitis classification considers different phenotypes characterized by the etiopathogenic mechanisms. The most common types include infectious rhinitis, allergic rhinitis, non-allergic rhinitis, vasomotor rhinitis, atrophic rhinitis, medicamentosa (iatrogenic)rhinitis, and hormonal rhinitis. Natural remedies are even more esteemed and requested by the patients.In this regard, Rinalt® is a Medical Device Class II CE formulated as a nasal spray. Rinalt® contains Mucotannil® complex, seawater, dexpanthenol, and essential balsamic oils. Rinalt® is an adjunctive treatment for respiratory disorders characterized by mucus hyperproduction, including infectious rhinitis and allergic rhinitis. This formulation results in a protective barrier against pathogens, allergens, irritants, and noxious substances. These effects are obtained thanks to the active components. Its components exert many activities, including antimicrobial, anti-inflammatory, antioxidant, decongestant, and mucolytic properties. Therefore, this product may be fruitfully used in clinical practice.
Keywords
References
Supporting Agencies
Copyright (c) 2022 S.E. Aragona, V. Camesasca, S. Lazzaro, G. Ciprandi
This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Medical Genetics, University of Torino Medical School, Italy
Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy